Alzheimer's - Dementia, Author Interviews, Lipids, Vanderbilt / 18.01.2026
Vanderbilt Study Provides Most Definitive Evidence To Date that APOE Contributes to SuperAging
MedicalResearch.com Interview with:
[caption id="attachment_72035" align="alignleft" width="200"]
Dr. Gaynor[/caption]
Leslie S. Gaynor, PhD
Clinical Neuropsychologist & Assistant Professor of Medicine
Division of Geriatric Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, TN 37203
MedicalResearch.com: What is the background for this study?
Response: The US population is rapidly aging, and the oldest members of our population are also the most vulnerable to developing clinical dementia. We are interested in studying older adults ages 80+ who display cognitive resilience despite this increased risk of dementia and actually display exceptional memory performance compared to their same-aged, typically performing peers. These “SuperAgers,”—i.e., 80+-year-old adults with memory performance that is comparable to or surpasses that of adults 20 to 30 years their junior—may hold the key to uncovering genetic factors that predict exceptionally healthy longevity.
Dr. Gaynor[/caption]
Leslie S. Gaynor, PhD
Clinical Neuropsychologist & Assistant Professor of Medicine
Division of Geriatric Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, TN 37203
MedicalResearch.com: What is the background for this study?
Response: The US population is rapidly aging, and the oldest members of our population are also the most vulnerable to developing clinical dementia. We are interested in studying older adults ages 80+ who display cognitive resilience despite this increased risk of dementia and actually display exceptional memory performance compared to their same-aged, typically performing peers. These “SuperAgers,”—i.e., 80+-year-old adults with memory performance that is comparable to or surpasses that of adults 20 to 30 years their junior—may hold the key to uncovering genetic factors that predict exceptionally healthy longevity.
Dr. Belloy[/caption]
Michael E. Belloy, PhD
Department of Neurology and Neurological Sciences
Stanford University, Stanford, California
MedicalResearch.com: What is the background for this study?
Response: Apolipoprotein E (APOE)*2 and APOE*4 are, respectively, the strongest protective and risk-increasing, genetic variants for late-onset Alzheimer disease. As such, one’s APOE genotype is highly relevant towards clinical trial design and Alzheimer’s disease research. However, most insights so far are focused on the associations of these APOE genotypes with Alzheimer’s disease risk in non-Hispanic white individuals.
One important aspect of our work is that we really increased sample sizes for non-Hispanic Black, Hispanic, and East Asian individuals, so that we now have better understanding of the associations of APOE genotypes with Alzheimer’s disease risk in these groups. In complement, we also did the largest investigation to date on the role of ancestry on the associations of APOE genotypes with Alzheimer’s disease risk. The scale of our study was thus a critical factor in generating novel insights.
